Table 1. Baseline characteristics
Group C:
with IS
N=32
Group C:
Without IS
N=85
P Value
Male gender, n (%)
12 (38)
27 (32)
0.6606
Age, years, mean (SD)
[min-max]
BMI, kg/m2, mean (SD)
[min-max]
40 (12)
[22-63]
25 (6)
[18–41]
37 (11)
[19–64]
24 (5)
[17–47]
0.3736
Active smoking, n (%)
14 (44)
52 (62)*
0.0949
Crohn’s disease, n (%)
21 (66)
71 (84)
0.0446
Duration of IBD, years, mean (SD)
[min-max]
Age at IBD, years, mean (SD)
[min-max]
Harvey-Bradshaw score (Crohn’s disease),
mean (SD) [min-max]
Mayo score (ulcerative colitis), mean (SD)
[min-max]
11 (9)
[1–32]
28 (10)
[12–58]
3.0 (2.6)
[0-8]
1.0 (1.7)
[0-5]
10 (7)
[0–33}
27 (9)
[9–51]
4.9 (4.6)
[0-22]
2.9 (2.7)
[0-8]
0.7923
At least one
11 (34)
15 (18)
0.0789
2008-2009
8 (26)
11 (13)*
0.1534
2007-2008
8 (26)
12 (14)*
0.1676
2006-2007
4 (13)
11 (13)*
0.9999
All 3 years
3 (10)
8 (9)*
0.9999
0.7902
0.6114
0.1691
0.0546
Influenza vaccination within past 3 years, n (%)
Pneumococcal vaccination within past 3 years, n
(%)
5 (16)
4 (5)
0.0618
Table 2. Immune response to first-year (2009–2010) influenza vaccine
A/H1N1
2007
A/H3N2
B
Group A:
no IS
N=31
Group B:
IS without
anti-TNF
N=77
Group C:
anti-TNF with or
without IS
N=117
Group C:
anti-TNF with IS
N=32
Group C:
anti-TNF
without IS
N=85
P-value
(4 groups)
PValue**
(C with
vs. C
without)
3/31 (10)
23/30 (77)
16/29 (55)
10/26 (38)
9/73 (12)
55/73 (75)
38/69 (55)
25/54 (46)
11/116 (9)
75/113 (66)
31/102 (30)
18/89 (20)
4/32 (13)
19/32 (59)
12/30 (40)
7/25 (28)
7/84 (8)
56/81 (69)
19/72 (26)
11/64 (17)
0.8327
0.3555
0.0024
0.0056
0.4926
0.3788
0.2372
0.2572
20/30 (67)
46/72 (64)
60/112 (54)
13/32 (41)
47/80 (59)
0.1216
0.0963
9.2 (31, 6.3–13)
74 (30, 46–119)
7.9 (30, 4.8–13)
9.4 (73, 7.3–12)
73 (73, 52–101)
7.7 (72, 5.5–11)
8.3 (116, 7.1–9.6)
57 (113, 44–73)
6.8 (112, 5.3–8.6)
9.7 (32, 6.9–14)
51 (32, 32–82)
5.3 (32, 3.4–8.1)
7.8 (84, 6.6–9.2)
59 (81, 43–80)
7.5 (80, 3.3–10.1)
0.5939
0.5427
0.5927
0.2183
0.6679
0.2236
5/31 (16)
23/30 (77)
15/29 (52)
12/26 (46)
13/73 (18)
50/73 (68)
31/69 (45)
21/53 (40)
10/115 (9)
59/113 (52)
18/103 (17)
11/88 (13)
6/32 (19)
16/32 (50)
4/30 (13)
3/25 (12)
4/83 (5)
43/81 (53)
14/73 (19)
8/63 (13)
0.0293
0.0350
<0.0001
<0.0001
0.0270
0.8358
0.5773
0.9999
19/30 (63)
36/72 (50)
45/111 (41)
13/32 (41)
32/79 (41)
0.1534
0.9999
GMT (N, 95% CI)
D0
D21
Fold increase D21/D0
11 (31, 8–16)
77 (30, 46–127)
6.5 (30, 4.0–11)
13 (73, 10–15)
53 (73, 39–71)
4.1 (72, 3.1–5.4)
10 (115, 9–12)
31 (113, 25–39)
3.2 (111,2.6–3.9)
12 (32, 8–17)
31 (32, 20–47)
2.6 (32,1.7–3.8)
9 (83, 8–11)
32 (81, 25–40)
3.5 (79,2.8–4.3)
0.1822
0.0014
0.0427
0.2386
0.9146
0.2127
Seroprotection, n/N (%)
D0
D21
M6
11/31 (35)
29/30 (97)
25/29 (86)
36/73 (49)
69/72 (96)
57/69 (83)
46/115 (40)
108/114 (95)
75/100 (75)
21/32 (66)
31/32 (97)
25/29 (86)
25/83 (30)
77/82 (94)
50/71 (70)
0.0026
0.9650
0.1661
0.0068
0.9999
0.1288
Seroprotection, n/N (%)
D0
D21
M6
M12
Seroconversion, n/N (%)
D21–D0
GMT (N, 95% CI)
D0
D21
Fold increase D21/D0
Seroprotection, n/N (%)
D0
D21
M6
M12
Seroconversion, n/N (%)
D21–D0
M12
21/26 (81)
43/53 (81)
56/88 (64)
20/24 (83)
36/64 (56)
Seroconversion, n/N (%)
D21–D0
19/30 (63)
54/71 (76)
68/113 (60)
15/32 (47)
53/81 (65)
GMT (N, 95% CI)
D0
22 (31, 16–30)
23 (73, 18–29)
24 (115, 20–28)
37 (32, 27–49)
20 (83, 16–25)
D21
162 (30, 106–249) 149 (72, 124–178) 115 (114, 99–134) 118 (32, 87–161) 114 (82, 95–137)
Fold increase D21/D0 7.0 (30, 4.1–12)
6.5 (71, 5.2–8.1) 5.0 (113, 4.0–6.2) 3.2 (32, 2.3–4.5)
5.9 (81, 4.5–7.8)
* In vaccine recipients only (N = 49: 8, 14 and 27 for the three groups, respectively); 12 patients received one dose, 37 received two doses.
0.0076
0.0247
0.0382
0.0887
0.0120
0.1325
0.0290
0.0008
0.8733
0.0216